Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($3.83) EPS, FY2025 earnings at ($3.75) EPS and FY2026 earnings at ($2.96) EPS.

SNDX has been the subject of several other reports. Barclays increased their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. UBS Group began coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price objective for the company. Stifel Nicolaus increased their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, October 14th. Bank of America increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.82.

Syndax Pharmaceuticals Trading Up 1.3 %

NASDAQ SNDX opened at $21.81 on Wednesday. Syndax Pharmaceuticals has a 52 week low of $13.14 and a 52 week high of $25.34. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -6.01 and a beta of 0.92. The company has a 50-day moving average price of $19.11 and a two-hundred day moving average price of $20.33.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter last year, the company posted ($0.73) EPS. As a group, equities research analysts expect that Syndax Pharmaceuticals will post -3.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several hedge funds have recently made changes to their positions in SNDX. Nvwm LLC purchased a new stake in shares of Syndax Pharmaceuticals in the 1st quarter valued at approximately $1,022,000. Swiss National Bank lifted its position in shares of Syndax Pharmaceuticals by 5.8% in the 1st quarter. Swiss National Bank now owns 150,600 shares of the company’s stock valued at $3,584,000 after acquiring an additional 8,200 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Syndax Pharmaceuticals in the 1st quarter worth approximately $2,614,000. Sei Investments Co. lifted its position in Syndax Pharmaceuticals by 2.5% in the 1st quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after buying an additional 991 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in Syndax Pharmaceuticals by 29.6% in the 1st quarter. ProShare Advisors LLC now owns 20,112 shares of the company’s stock worth $479,000 after buying an additional 4,599 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).